U.S. Software Stock News

If you are wondering whether Recursion Pharmaceuticals' current share price makes sense, the key question is how that price compares with what the business could reasonably be worth. The stock last closed at US$3.67, with a 7 day return of 7.3%, a 30 day return decline of 12.4%, a year to date return decline of 12.6%, and a 1 year return decline of 51.1%. These figures will shape how many investors think about its potential and risk today. Recent coverage has focused on Recursion...

GoodRx Holdings recently reported fourth-quarter 2025 results, issued 2026 revenue guidance of US$750 million to US$780 million, updated progress on its share buyback, filed a US$74.72 million shelf registration for an ESOP-related Class A stock offering, and disclosed several analyst rating changes. The company also launched GoodRx Employer Direct, a new program that lets employers directly subsidize high-cost drugs like GLP-1s at the pharmacy counter, potentially widening GoodRx’s role in...

National HealthCare Corporation reported past fourth-quarter 2025 revenue of US$386.51 million and net income of US$24.85 million, with full‑year 2025 revenue of US$1.52 billion and net income of US$120.02 million, all higher than the prior year. The company highlighted that growth was supported both by higher same‑facility revenues and the contribution from its White Oak Manor acquisition, underscoring the role of expansion alongside core operations in its 2025 results. With this backdrop...

Why Pacira BioSciences is on investors’ radar today Pacira BioSciences (PCRX) has been drawing attention after a mixed share price pattern, with a 6.7% gain over the past month contrasting with negative returns over the past 3 months and year to date. See our latest analysis for Pacira BioSciences. At the current share price of $21.91, Pacira BioSciences shows a mixed picture, with a 6.7% 30 day share price return set against a 10.4% year to date share price decline and a 68.3% five year...

With no fresh headline driving Inter & Co (NasdaqGS:INTR) today, recent performance and fundamentals come into focus as investors weigh its returns profile against revenue of R$5,984.585 and net income of R$1,312.39. See our latest analysis for Inter & Co. Inter & Co’s share price has eased in the short term, with a 7 day share price return of 5.84% and 30 day share price return of 6.65%, yet its 1 year total shareholder return of 64.56% and 3 year total shareholder return of almost 4x...

Concentra Group Holdings Parent, Inc. recently reported its fourth-quarter and full-year 2025 results, with Q4 revenue rising to US$539.08 million and net income to US$34.69 million, while also declaring a US$0.0625 per-share cash dividend payable in March 2026. Management is pairing this earnings momentum with expansion plans focused on smaller, bolt-on acquisitions and a stepped-up de novo clinic pipeline, supported by a new US$100.00 million share repurchase program. We’ll now examine how...

In late February 2026, Axos Financial, a digital-focused US bank, was caught in a broad financial sector downturn after a higher-than-expected January Producer Price Index reading reinforced concerns about persistent inflation and constrained room for near-term Federal Reserve rate cuts. This inflation surprise matters for Axos because sustained elevated rates can pressure bank net interest margins, directly affecting how profitably it turns deposits into loans and other interest-earning...

Agree Realty (ADC) has drawn attention after its recent share performance, with the stock last closing at $80.48. For income focused investors, the real estate investment trust’s profile may warrant a closer look. See our latest analysis for Agree Realty. The recent 11.8% 1 month share price return, on top of an 11.6% year to date share price return, sits alongside a 5 year total shareholder return of 54.4%, suggesting momentum has been building over both shorter and longer horizons. If this...

Xponential Fitness (XPOF) is back in focus after reporting fourth quarter and full year 2025 results, along with 2026 revenue guidance that points to a lower range than the prior year. See our latest analysis for Xponential Fitness. The earnings release and lower 2026 revenue guidance have coincided with sharp share price weakness, with a 1 day share price return of 47.08% decline and a 1 year total shareholder return of 67.75% decline. This points to fading momentum and a reassessment of...

In recent days, Cathay General Bancorp has come under pressure as investors reacted to rising credit risk concerns amid hotter-than-expected inflation data and growing worries over regional banks’ exposure to commercial real estate. What makes this episode especially important is that it coincides with Cathay General’s flat sales and declining earnings per share, sharpening questions about its profitability and growth profile. We’ll now examine how heightened credit risk concerns,...

Earnings, guidance and capital returns in focus Bristow Group (VTOL) just paired its fourth quarter and full year 2025 results with 2026 guidance, a fresh quarterly dividend and details on a recent US$500 million refinancing at a lower coupon. The company reported Q4 2025 sales of US$377.26 million and net income of US$18.42 million, while affirming 2026 revenue expectations in a US$1.58 billion to US$1.69 billion range and maintaining its new US$0.125 quarterly cash dividend. See our latest...

In February 2026, Federal Agricultural Mortgage Corporation reported fourth-quarter 2025 net income of US$47.92 million, down from US$56.51 million a year earlier, while full-year net income was broadly flat at US$207.42 million, and its board approved higher dividends on both common and preferred shares. Beyond the headline earnings softness, Farmer Mac’s fifteenth consecutive annual increase in its common dividend, alongside growth in infrastructure finance such as broadband and renewable...

Manchester United plc has reported fiscal second-quarter 2026 results, with sales of £190.31 million and a net income of £4.18 million, marking a return to profit despite lower revenue than the same period a year ago. The earnings improvement stems largely from cost and headcount reductions that turned a prior-period loss into a profit, while management reiterated full-year revenue guidance of £640 million to £660 million. We’ll now look at how this cost-driven profitability turnaround,...

If you are wondering whether Spectrum Brands Holdings is still attractively priced or already reflecting its potential, you are in the right place for a clear, valuation focused look at the stock. The share price recently closed at US$78.38, with returns of 23.0% over 30 days and 30.5% year to date, while the 1 year return sits at 4.4% and the 3 and 5 year returns are 28.8% and 8.8% respectively. This naturally raises questions about how much value is already priced in. Recent news around...

Claritev Corporation recently reported past fourth-quarter 2025 sales of US$246.55 million and a net loss of US$80.57 million, alongside full-year 2025 sales of US$965.41 million and a net loss of US$284.28 million, and announced a new share repurchase program of up to US$75 million running through 2030. While the company remains loss-making, the year-on-year reduction in losses and the commitment to buying back shares suggest management is focused on improving financial discipline and...

Glaukos (GKOS) is back in focus after its fourth quarter 2025 report paired strong sales figures with a sizeable impairment charge, followed shortly by fresh 2026 sales guidance and a new ESOP related shelf registration. See our latest analysis for Glaukos. The recent impairment charge and ESOP related shelf registration come against a backdrop of steady share price gains, with a 90 day share price return of 13.28% and a very large 3 year total shareholder return of 139.03%. This suggests...

Xeris Biopharma recently filed a Hatch-Waxman patent infringement lawsuit in the US District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics, seeking to block generic versions of its Cushing’s syndrome therapy Recorlev until its patents expire in March 2040. This legal move highlights how central Recorlev’s intellectual property protection is to Xeris’s long-term product exclusivity and potential revenue longevity in its endocrine...

Omnicell has recently accelerated its shift from hardware-focused sales toward software and services, including acquiring ANiGENT in October 2025 to broaden its drug diversion detection capabilities and recurring revenue base. This pivot toward subscription-like revenue streams is prompting investors to reassess Omnicell less as a traditional equipment maker and more as a healthcare IT provider, with different expectations for growth, risk and valuation. Next, we’ll examine how Omnicell’s...

Owens Corning (NYSE:OC) reported a net loss for the fourth quarter, reversing net income from the same period a year earlier. The company also posted a full year net loss, a material deterioration compared with the prior year's profitability. Recent results came in below earnings expectations, highlighting weaker than anticipated financial performance. For investors watching NYSE:OC, this shift to losses comes with the stock recently closing at $122.07. Shares are down 8.0% over the past...

If you are wondering whether Boise Cascade's share price still reflects its real worth, looking at how the market has treated the stock over different time frames is a useful starting point. The stock last closed at US$82.74, with returns of 0.7% over 7 days, 3.0% over 30 days, 11.6% year to date, but a 19.3% decline over 1 year and longer term returns of 36.4% over 3 years and 107.2% over 5 years. Recent headlines around Boise Cascade have focused on its position as a major supplier of...

FDA lifts clinical hold on Intellia Therapeutics' MAGNITUDE-2 ATTR amyloidosis trial, allowing global enrollment to resume with updated safety protocols. Intellia completes phase 3 enrollment ahead of schedule in the HAELO trial for lonvo-z, a one time gene editing therapy for hereditary angioedema. These steps advance Intellia Therapeutics' late stage pipeline and move its gene editing candidates closer to potential approval and commercialization. For investors watching Intellia...

If you are trying to work out whether Lineage at around US$40.52 is a bargain or just fairly priced, you are in the right place. The stock has recently posted returns of 5.8% over 7 days, 12.6% over 30 days and 14.4% year to date, although the 1 year return sits at a 29.3% decline. Recent attention on Lineage has focused on its position in the US real estate space and how investors are reassessing companies in the sector, which helps frame these recent price moves. Coverage has regularly...

Hyatt Hotels (NYSE:H) announced the retirement of Executive Chairman Thomas J. Pritzker after more than two decades in the role. The move comes alongside public mention of Pritzker's past association with Jeffrey Epstein and Ghislaine Maxwell. Hyatt has appointed current CEO Mark S. Hoplamazian as the new Chairman, concentrating leadership in a single figure. The transition highlights both succession planning and governance considerations for the company. For you as an investor, the key...

Why Aspen Aerogels is back in focus Aspen Aerogels (ASPN) is back on investors’ radar after reporting a sharp year over year revenue decline, a large full year net loss, a sizeable impairment charge, and guidance indicating continued losses. See our latest analysis for Aspen Aerogels. The stock’s recent swings reflect this reset in expectations, with a 7 day share price return showing a 13.57% decline and a 1 year total shareholder return indicating a 59% loss, highlighting how pressure has...